Table I.
Clinicopathological and immunohistochemical findings in 15 cases of ATC and 13 cases of PDTC in 26 patients.
| Case no. | Age, years | Sex | Diagnosis | Follow-up (months) | PD-L1 TPS, % | PD-L1 TILs, % | CD3 | CD3 | CD8 | CD20 | CD68 | CD163 | S100 | p53 | MLH1 | MSH2 | MSH6 | PMS2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 73 | F | ATC, Sc | DOD (11.2) | 0 | 0 | 3 | 0 | 1 | 1 | 3 | 3 | 2 | B | + | + | + | + |
| 2 | 83 | F | ATC, Gc | DOD (0.13) | 15 | 20 | 3 | 1a | 3 | 0 | 3 | 3 | 1 | B | + | + | + | + |
| 3 | 67 | M | ATC, Sc | DOD (5.5) | 0 | 1 | 3 | 0 | 1 | 0 | 3 | 3 | 3 | WT | + | + | + | + |
| 4 | 75 | M | ATC, Gc | DOD (1) | 0 | 0 | 3 | 1a | 2 | 1 | 3 | 3 | 1 | N | + | + | + | + |
| 5 | 76 | F | ATC, Ec | DOD (0.03) | 35 | 5 | 3 | 1a | 3 | 0 | 3 | 3 | 1 | WT | + | + | + | + |
| 6b | 73 | M | ATC, Sc | DOD (1.56) | 30 | 3 | 3 | 0 | 3 | 0 | 3 | 3 | 1 | WT | + | + | + | + |
| 7 | 68 | F | ATC, Gc | DOD (0.36) | 15 | 15 | 3 | 1a | 3 | 0 | 3 | 3 | 1 | B | + | + | + | + |
| 8 | 47 | M | ATC, Gc | DOD (16) | 0 | 5 | 3 | 1a | 3 | 1 | 3 | 3 | 1 | WT | + | + | + | + |
| 9 | 47 | F | ATC, Ec | DOD (2.73) | 18 | 0 | 3 | 0 | 2 | 1 | 3 | 3 | 1 | B | + | + | + | + |
| 10 | 60 | F | ATC, Gc | DOD (6) | 33 | 0 | 3 | 0 | 2 | 0 | 3 | 3 | 1 | B | + | + | + | + |
| 11 | 71 | M | ATC, Gc | DOD (1.6) | 0 | 1 | 3 | 0 | 3 | 1 | 3 | 3 | 1 | B | + | + | + | + |
| 12 | 67 | F | ATC, Ec | DOD (1.67) | 90 | 10 | 3 | 2a | 2 | 1 | 3 | 3 | 1 | B | + | + | + | + |
| 13 | 54 | F | ATC, Gc | DOD (7) | 30 | 20 | 3 | 1a | 2 | 1 | 3 | 3 | 2 | N | + | + | + | + |
| 14c | 52 | M | ATC, Gc | AWD (14) | 0 | 10 | 2 | 1a | 2 | 0 | 3 | 3 | 1 | B | + | + | + | + |
| 15b | 55 | F | ATC, Gc | AWD (7) | 90 | 80 | 3 | 1a | 3 | 0 | 3 | 3 | 2 | B | − | + | + | − |
| 15b | 55 | F | PDTC | AWD (7) | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | WT | + | + | + | + |
| 6b | 73 | M | PDTC | DOD (1.56) | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | WT | + | + | + | + |
| 16 | 72 | F | PDTC | AAW (237) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | WT | + | + | + | + |
| 17 | 75 | M | PDTC | DOD (12.6) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | WT | + | + | + | + |
| 18 | 68 | F | PDTC | DAD (148.2) | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | WT | + | + | + | + |
| 19 | 71 | F | PDTC, Oc | DOD (149.88) | 35 | 0 | 2 | 0 | 2 | 0 | 2 | 2 | 1 | B | − | + | + | − |
| 20 | 78 | F | PDTC | DOD (99.24) | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | WT | + | + | + | + |
| 21 | 73 | F | PDTC | DOD (5.52) | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | WT | + | + | + | + |
| 22 | 80 | F | PDTC | DOD (3.36) | 0 | 0 | 1 | 0 | 2 | 0 | 1 | 1 | 1 | WT | + | + | + | + |
| 23 | 75 | F | PDTC | DAD (58.32) | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | WT | + | + | + | + |
| 24 | 87 | F | PDTC | DOD (29.16) | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | WT | + | + | + | + |
| 25 | 63 | F | PDTC | AWD (99.24) | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | WT | + | + | + | + |
| 26 | 67 | M | PDTC | AWD (84) | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1a | WT | + | + | + | + |
Positivity exclusively in lymphoid population surrounding the tumor
These tumors combined areas of ATC and PDTC
This was the only case with a previous diagnosis as a differentiated thyroid carcinoma (Hürthle cell carcinoma diagnosed 26 months earlier). M, male; F, female; ATC, anaplastic thyroid carcinoma; PDTC, poorly differentiated thyroid carcinoma; Sc, spindle cell sarcoma-like pattern; Gc, giant cell pattern; Ec, epithelial cell pattern; Oc, oncocytic variant (Hürthle cell PDTC); DOD, dead of disease; AWD, alive with disease; AAW, alive and well; DAD, dead from another disease; TPS, tumor proportion score; TILs, tumor-infiltrating lymphocytes; 1, ≤10% positivity of inflammatory cells; 2, 11–49% positivity; 3, ≥50% positivity; B, ‘block’ staining; N, ‘null’ phenotype; WT, wild-type; PD-L1, programmed death ligand 1; MLH1, mutL homolog 1; MSH2, mutS homolog 2; MSH6, mutS homolog 6; PMS2, PMS1 homolog 2.